BTAI vs CRDL Valuation Comparison 2026 — Intrinsic Value Analysis

Quick Summary — CRDL scores higher on quality with 6.2/10 vs BTAI's 4.4/10. BTAI trades at $1.19 while CRDL trades at $1.15. Both analyzed daily using SEC EDGAR data across 13 institutional models.

BTAI

Drug Manufacturers - Specialty & Generic

BioXcel Therapeutics, Inc.

Quality

4.4

out of 10

Value Trap

24

SAFE

Price

$1.19

Last close

Models

4/13

Active

VS

CRDL

Drug Manufacturers - Specialty & Generic

Cardiol Therapeutics Inc.

Quality

6.2

out of 10

Value Trap

12

SAFE

Price

$1.15

Last close

Models

9/13

Active

BTAI

PWERM sees +208.4% upside

Quality 4.4/10 — below average

CRDL

2 models active

Limited to 2/13 visible models

BTAI vs CRDL — Fair Value Comparison

BTAI

CRDL

Market Price Model 1 Model 2

Model-by-Model Comparison

Model	Type	BTAI Fair Value	BTAI Upside	CRDL Fair Value	CRDL Upside
Bayesian DCF	Intrinsic	—	—	$0.38	-67.3%
EROIC Spread	Intrinsic	$1.49	+24.3%	—	—
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	—	—	$0.17	-85.2%
PWERM	Option-Based	$3.67	+208.4%	$1.12	-2.7%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

BTAI vs CRDL — Which Stock Is More Undervalued in 2026?

CRDL scores higher with a 6.2/10 quality rating vs BTAI's 4.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

How Do BTAI and CRDL Valuations Compare?

BTAI currently trades at $1.19 while CRDL trades at $1.15. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily for both companies.

Quality of Company: BTAI vs CRDL

BTAI earns a Quality of Company score of 4.4/10 compared to CRDL's 6.2/10. This moderate difference suggests one company has an edge in fundamental quality, though both may offer investment merit depending on valuation. The QOC score synthesizes 32 signals spanning profitability margins, revenue growth, free cash flow, capital allocation, and leverage.

Value Trap Risk: BTAI vs CRDL

BTAI carries a SAFE value trap risk (24/100) while CRDL shows SAFE risk (12/100). Both companies show manageable value trap risk, suggesting their current valuations are not artificially depressed by fundamental deterioration.

Both in Drug Manufacturers - Specialty & Generic

Both BTAI and CRDL operate in Drug Manufacturers - Specialty & Generic, which has 79 stocks tracked by CirclFi. Same-industry comparisons provide the most direct insight into relative valuation since both companies face similar regulatory environments, market dynamics, and competitive pressures. Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN), and ensemble methods (CUCE).

2 of 13 MODELS UNLOCKED

You’re comparing 2 models. 11 more have an opinion.

11 hidden models compare BTAI vs CRDL differently — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more. Some may disagree with the 2 you see above.

11 additional fair values per stock Full confidence breakdown Live terminal — 5,000+ stocks

Bloomberg Terminal: ~$2,000/mo · FactSet: ~$1,000/mo · CirclFi: $0.90/day

See All 13 Models — $0.90/day

We don’t predict prices. We show you what 13 independent mathematical frameworks say a stock is worth — and let you decide.

BTAI

View Full BioXcel Therapeutics, Inc. Analysis →

CRDL

View Full Cardiol Therapeutics Inc. Analysis →

See all Drug Manufacturers - Specialty & Generic stocks →